GSK plc is a pharmaceutical manufacturer headquartered in London that researches, develops, and produces vaccines, specialty medicines, and general medicines for disease prevention and treatment. The company operates across multiple therapeutic areas, including oncology, respiratory and immunology conditions, and HIV. Its vaccine portfolio spans infectious diseases such as shingles, meningitis, RSV, seasonal influenza, hepatitis, and human papillomavirus, among others. The general medicines business addresses conditions including asthma, chronic obstructive pulmonary disease, and bacterial infections.
The company structures its operations through Commercial Operations and Total R&D segments. Specialty medicines represent a significant portion of the business, addressing conditions like lupus nephritis, eosinophilic respiratory diseases, and ovarian cancer. GSK maintains collaborative agreements with external partners, including CureVac for mRNA vaccine development and AN2 Therapeutics for tuberculosis therapeutic development.
GSK operates globally with a substantial presence in the United Kingdom, United States, and international markets. The company traces its origins to 1715 and rebranded from GlaxoSmithKline plc to GSK plc in May 2022. It trades on the New York Stock Exchange and maintains the scale typical of major multinational pharmaceutical manufacturers, with operations spanning research, manufacturing, and commercial distribution across numerous countries.
No 10-K filings found.